Safety and Immune Response Study of GSK Biologicals' Influenza Virus Vaccine 1388442A Compared With Fluarix

Inclusion Criteria:

- Subjects who the investigator believes can and will comply with the requirements of
the protocol

- A male or non-pregnant, non-lactating female between 18 and 49 years of age at the
time of vaccination

- Access to a telephone for scheduled follow-up telephone contacts

- Ability to provide written informed consent

- Healthy subjects as established by medical history and physical examination before
entering into the study

- If the subject is female, she must be of non-childbearing potential, or if she is of
childbearing potential, she must practice adequate contraception for 30 days prior to
vaccination and continue such precautions for 2 months after receipt of the study
vaccine. All women will have a pregnancy test on the day of vaccination.

Exclusion Criteria:

- Use of any investigational or non-registered product (drug or vaccine) other than the
study vaccine within 30 days preceding the dose of study vaccine, or planned use
during the study period

- Receipt of systemic glucocorticoids within 30 days of study enrollment

- Administration of immunosuppressant, cytotoxic, or other immune-modifying drugs (other
than glucocorticoids) or irradiation within 6 months prior to study enrollment or
planned administration during the study period

- Administration of immunoglobulins and/or blood products within 3 months prior to study
enrollment or planned administration during the study period

- Previous vaccination against influenza (2007-2008 influenza season)

- History of anaphylactic or other allergic reaction to influenza vaccine, any other
vaccine, or any vaccine component or excipient

- History of Guillain-Barre Syndrome (GBS)

- Acute disease, febrile illness, or upper respiratory infection at screening.

- History of splenectomy

- Any confirmed or suspected, acquired, congenital, or hereditary immunodeficiency or
immunosuppressive condition (including human immunodeficiency virus [HIV]) based on
medical history and physical examination

- Acquired or congenital coagulation disorders or known thrombocytopenia

- Current treatment with warfarin or heparin derivatives

- Known use of an analgesic or antipyretic medication within 12 hours prior to treatment
for the purposes of prophylaxis of adverse events

- Any medical condition for which the US Advisory Committee on Immunization Practices
recommends vaccination against influenza